tiprankstipranks

Sana Biotechnology initiated with a Neutral at H.C. Wainwright

H.C. Wainwright initiated coverage of Sana Biotechnology with a Neutral rating and no price target. Although preclinical data and an experienced management team "add promise" to Sana’s approach, the company’s programs are still in the early innings, and its market cap of $1B is pricing in a high probability of success, the analyst tells investors in a research note. The firm believes this creates an unfavorable risk/reward going into initial clinical data in the second half of 2023.

Confident Investing Starts Here:

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on SANA:

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue